Publications

The nasal mucosal late allergic reaction to grass pollen involves type 2 inflammation (IL-5 and IL-13), the inflammasome (IL-1β), and complement.

A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients.

A novel flow cytometric-based method to measure kinase inhibition in sputum from COPD subjects.

Using magnetic resonance imaging to quantify the inflammatory response following allergen challenge in allergic rhinitis.

Bronchoabsorption; a novel bronchoscopic technique to improve biomarker sampling of the airway.

The novel inhaled glucocorticoid receptor agonist GW870086X protects against adenosine-induced bronchoconstriction in asthma.

The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild to moderate asthma.

Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease.

The effect of the novel phosphodiesterase-4 inhibitor MEM 1414 on the allergen induced responses in mild asthmatics.

Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics.

Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist.

Rapid effects of extrafine beclomethasone dipropionate/formoterol fixed combination inhaler on airway inflammation and bronchoconstriction in asthma: a randomised controlled trial.

Safety of Regadenoson, an A2A receptor agonist for myocardial perfusion imaging in asthmatic patients: a randomised double blind placebo controlled trial.

Enquire today

Contact us to discuss how RCT can assist your organisation with the design, implementation and management of clinical trials.

We use cookies to understand better how the site is used. By continuing to use this site, you will agree to this policy. Click to learn more.